You are here: Industry Insights > SPN-812

News List

Supernus Resubmits NDA for SPN-812 for ADHD in Pediatric Patients americanpharmaceuticalreview
February 10, 2021
Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for SPN-812 for the treatment of ADHD in pediatric patients.
Supernus Announces Positive Results from SPN-812 Study for ADHD americanpharmaceuticalreview
December 31, 2020
Supernus Pharmaceuticals has announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).
Supernus Provides Regulatory Updates for SPN-812 and SPN-830 americanpharmaceuticalreview
November 20, 2020
Supernus Pharmaceuticals announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for ...
Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812 fiercebiotech
December 29, 2018
Supernus Pharmaceuticals unveiled topline results from two phase 3 studies of children with attention deficit hyperactivity disorder but failed to wow investors worried about how its nonstimulant treatment would take on already-established generics.....
Supernus says ADHD drug trounces rivals, but shares slide pharmaphorum
December 10, 2018
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.